Compounds > carbamates
Page last updated: 2024-10-16

carbamates and Enterically-Transmitted Non-A, Non-B Hepatitis

carbamates has been researched along with Enterically-Transmitted Non-A, Non-B Hepatitis in 1 studies

Research Excerpts

ExcerptRelevanceReference
" Twelve weeks long treatment with sofsobuvir, daclatasvir, ribavirin, and tenofovir resulted in sustained virological response (SVR) and cleared HBV, HCV, and HEV in diabetic and asthmatic patient."3.96Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report. ( Wahid, B, 2020)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Wahid, B1

Other Studies

1 other study available for carbamates and Enterically-Transmitted Non-A, Non-B Hepatitis

ArticleYear
Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report.
    Journal of infection and public health, 2020, Volume: 13, Issue:1

    Topics: Aged; Antiviral Agents; Asthma; Carbamates; Coinfection; Diabetes Complications; Drug Administration

2020